This article was originally published in The Gray Sheet
Stryker CFO retires and Osiris Therapeutics CEO resigns, as SpineGuard and Tandem Diabetes Care expand management teams.
You may also be interested in...
Tandem Diabetes Care’s t:slim G4 insulin pump/continuous glucose monitor system is the latest DexCom partnership to yield an FDA approval, and the first integrated diabetes system to feature a touch-screen display.
In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?